AbbVie Nears $10.9B Acquisition of Apogee Therapeutics
AbbVie is reportedly close to a $10.9 billion deal to acquire Apogee Therapeutics, signaling continued big-pharma appetite for biotech assets.
AbbVie is nearing a deal to acquire Apogee Therapeutics in a transaction valued at approximately $10.9 billion, according to reports cited by Seeking Alpha. The potential acquisition underscores the ongoing consolidation wave sweeping the pharmaceutical industry, as large drugmakers seek to replenish pipelines and offset revenue pressures from patent expirations on blockbuster treatments.
Apogee Therapeutics is a clinical-stage biotech focused on developing antibody-based therapies for inflammatory and immunological diseases — a therapeutic area where AbbVie already holds considerable commercial strength through its flagship immunology portfolio. A deal of this scale would represent one of the more significant biotech acquisitions of the year, reflecting how competitively companies are bidding for differentiated, late-stage or near-commercial assets.
Read more Apple to Raise Prices as Memory Costs Hit Breaking Point →
For AbbVie, the strategic logic is straightforward. The company has been actively diversifying its revenue base following the long-anticipated biosimilar erosion of Humira, once the world's best-selling drug. Acquiring a company with a promising immunology pipeline would directly address that vulnerability, potentially giving AbbVie next-generation assets to sustain its dominance in that therapeutic category.
More broadly, this reported deal fits a pattern visible across the industry: cash-rich pharmaceutical giants are using M&A as a faster, more predictable route to innovation than internal R&D alone. Regulatory scrutiny of large mergers has intensified in recent years, but deals structured around clinical-stage biotechs — rather than established commercial competitors — have generally faced a cleaner path to approval. Whether this transaction closes at the reported valuation remains to be seen, but the reported price tag alone signals strong conviction in Apogee's underlying science.
Continue reading at SeekingAlpha.
